Similar articles for PMID: 33219158

Year	Number of Results
2013	3
2014	10
2015	12
2016	17
2017	16
2018	26
2019	21
2020	22
2021	8

1

Review of Palliative ²²³Ra in Metastatic Castration-Resistant Prostate Cancer: Experience at West Virginia University Cancer Center.

Arays R, Ahmad Z, Howard L, Veselicky K, Kolodney J, SijinWen, Hogan T. Arays R, et al. J Nucl Med Technol. 2021 Mar;49(1):70-74. doi: 10.2967/jnmt.120.254474. Epub 2020 Nov 20. J Nucl Med Technol. 2021. PMID: 33219158

2

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators. Saad F, et al. Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26. Lancet Oncol. 2016. PMID: 27473888 Clinical Trial.

3

The Prognostic Value of Quantitative Bone SPECT/CT Before ²²³Ra Treatment in Metastatic Castration-Resistant Prostate Cancer.

Dittmann H, Kaltenbach S, Weissinger M, Fiz F, Martus P, Pritzkow M, Kupferschlaeger J, la Fougère C. Dittmann H, et al. J Nucl Med. 2021 Jan;62(1):48-54. doi: 10.2967/jnumed.119.240408. Epub 2020 May 22. J Nucl Med. 2021. PMID: 32444369

4

Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.

Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K. Lavaud P, et al. Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23. Eur Urol. 2018. PMID: 29074061 Clinical Trial.

5

Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer.

Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, Choo CR, Tzou KS, Bryce AH, Ho TH, Quevedo FJ, Vora SA. Wong WW, et al. Clin Genitourin Cancer. 2017 Dec;15(6):e969-e975. doi: 10.1016/j.clgc.2017.04.016. Epub 2017 Apr 26. Clin Genitourin Cancer. 2017. PMID: 28545997

6

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Hoskin P, et al. Lancet Oncol. 2014 Nov;15(12):1397-406. doi: 10.1016/S1470-2045(14)70474-7. Epub 2014 Oct 17. Lancet Oncol. 2014. PMID: 25439694 Clinical Trial.

7

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ. Francini E, et al. Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27. Clin Genitourin Cancer. 2018. PMID: 29331381 Free PMC article. Clinical Trial.

8

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology. Heidenreich A, et al. Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Eur Urol. 2014. PMID: 24321502 Review.

9

Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.

Yamamoto Y, Okuda Y, Kanaki T, Tanaka R, Nagahara A, Nakai Y, Nakayama M, Kakimoto KI, Nishimura K. Yamamoto Y, et al. Int J Clin Oncol. 2021 Jan;26(1):192-198. doi: 10.1007/s10147-020-01776-w. Epub 2020 Sep 1. Int J Clin Oncol. 2021. PMID: 32875513

10

A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.

Badrising SK, Louhanepessy RD, van der Noort V, Coenen JLLM, Hamberg P, Beeker A, Wagenaar N, Lam MGEH, Celik F, Loosveld OJL, Oostdijk A, Zuetenhorst H, Haanen JB, Vegt E, Zwart W, Bergman AM; ROTOR investigators and the Dutch Uro-Oncology Study group (DUOS15101). Badrising SK, et al. Int J Cancer. 2020 Aug 15;147(4):1143-1151. doi: 10.1002/ijc.32851. Epub 2020 Jan 21. Int J Cancer. 2020. PMID: 31875956 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed